TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32241789
Drug: True acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: True acupuncture treatment
Study: 32049937
Drug: Weekly teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly teriparatide (WT) from 1 week to 6 months postoperatively
Study: 35465375
Drug: Standard ward
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ward pre-operative preparation procedures
Study: 33055078
Drug: Tocilizumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (8 mg/kg intravenous, two infusions 4 weeks apart)
Study: 32602828
Drug: Transarterial radioembolization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transarterial radioembolization (TARE) with a tumor radiation-absorbed dose greater than or equal to 100 Gy (n = 67)
Study: 32602828
Drug: Transarterial radioembolization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transarterial radioembolization (TARE) with tumor radiation-absorbed dose greater than or equal to 100 Gy and optimal agreement
Study: 34157632
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose (FCM) 1500 mg
Study: 33864548
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual (TAU) (n=33)
Study: 32915043
Drug: hypCPT (cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: hypCPT (cognitive processing therapy + hypnosis)
Study: 32915043
Drug: ssmCPT (sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: ssmCPT (sleep and psychiatric symptom monitoring plus cognitive processing therapy)
Study: 32432718
Drug: Polymer-free, biolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymer-free, biolimus A9-eluting drug-coated stent with 1-month dual antiplatelet therapy
Study: 34489860
Drug: Metformin only
Normalized name: Metformin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin only (Control)
Study: 35121639
Drug: adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: adalimumab 40 mg
Study: 34984839
Drug: Repository corticotropin
Normalized name: Repository Corticotropin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repository corticotropin injection (RCI, 80 U)
Study: 32979620
Drug: Topical tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical tranexamic acid (TXA) prior to TBLB
Study: 33073298
Drug: Adipose tissue
Normalized name: Autologous stromal vascular fraction from adipose tissue
DrugBank: Autologous adipose-derived stromal vascular fraction cells (DB18679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adipose tissue stem cell-derived exosomes gel
Study: 34550563
Drug: Dexmedetomidine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.2 µg kg-1 h-1)
Study: 34550563
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (0.5 ml kg-1 h-1)
Study: 33176942
Drug: JUUL System
Approvals — FDA: no, EMA: no, PMDA: no
Description: JUUL System (JS) in four flavors (Virginia Tobacco, Mango, Mint, Creme, [5.0 % nicotine; 59 mg/mL])
Study: 38695479
Drug: Pembrolizumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab + chemotherapy
Study: 36410666
Drug: Daily TPTD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily TPTD (20 μg daily)
Study: 36410666
Drug: Cyclic TPTD
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic TPTD (20 μg daily for 3 months followed by 3 months off)
Study: 36432461
Drug: Daily walnut
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily walnut consumption
Study: 32533012
Drug: GG genotype
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GG genotype at rs4680 G > A
Study: 32533012
Drug: CC genotype
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC genotype at rs4633
Study: 36362620
Drug: Intensified clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified clinical pharmacological/pharmaceutical care program
Study: 33087145
Drug: Re-esterified DHA
Normalized name: Esterified Estrogens
DrugBank: Esterified estrogens (DB09381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-esterified DHA (975 mg for 30 days)
Study: 38050037
Drug: Dupilumab 300
Normalized name: dupilumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 300 mg once a week
Study: 33596968
Drug: Bilateral ultrasound-guided
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral ultrasound-guided ESP block with 40 ml 0.25% levo-bupivacaine (20 ml each side) post induction of general anaesthesia and before surgical incision.
Study: 33596968
Drug: Standardised analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised analgesic protocol (same for both groups).
Study: 35271495
Drug: Intravenous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitamin C (ascorbic acid) administered three times a week for three months
Study: 35340961
Drug: 0.5% isobaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% isobaric levobupivacaine with 75‐mg magnesium sulfate
Study: 35340961
Drug: 0.5% hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% hyperbaric bupivacaine with 75‐mg magnesium sulfate
Study: 32951292
Drug: Gracilaria algae
Normalized name: GRACILARIA GRACILIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gracilaria algae cream 3%
Study: 32951292
Drug: Clobetasol cream
Normalized name: clobetasol Topical Cream
DrugBank: Clobetasol (DB11750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobetasol cream 0.05%
Study: 35706490
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg intravenous ferric carboxymaltose (iron)
Study: 33961310
Drug: Domagrozumab 5
Normalized name: Domagrozumab
DrugBank: Domagrozumab (DB15083)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domagrozumab 5 mg/kg every 4 weeks
Study: 33961310
Drug: Domagrozumab 20
Normalized name: Domagrozumab
DrugBank: Domagrozumab (DB15083)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domagrozumab 20 mg/kg every 4 weeks
Study: 33961310
Drug: Domagrozumab 40
Normalized name: Domagrozumab
DrugBank: Domagrozumab (DB15083)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domagrozumab 40 mg/kg every 4 weeks
Study: 35759733
Drug: Paclitaxel (P)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel (P) 135 mg/m2 once every 28 days for 12 cycles
Study: 35759733
Drug: Paclitaxel poliglumex
Normalized name: PACLITAXEL POLIGLUMEX
DrugBank: Paclitaxel poliglumex (DB13809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel poliglumex (PP) 135 mg/m2 once every 28 days for 12 cycles
Study: 34530679
Drug: Wait-list condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wait-list condition with treatment advice (WL/TA)
Study: 32049627
Drug: Phosphate content
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate content in medications prescribed to HD patients
Study: 32049627
Drug: Monitoring of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monitoring of medications containing phosphate
Study: 34969033
Drug: Treat-and-extend (T&E)
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treat-and-extend (T&E) regimen with intravitreal ranibizumab 0.5 mg
Study: 34969033
Drug: Once-monthly to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-monthly to treat-and-extend (OM-T&E) regimen with intravitreal ranibizumab 0.5 mg
Study: 34969033
Drug: Once-monthly to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-monthly to treat-and-extend (OM-T&E) regimen
Study: 36190330
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of SAp and SAm
Study: 32965037
Drug: High-dose melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose melatonin (4 mg for <40 kg; 8 mg for ≥40 kg)
Study: 32965037
Drug: Low-dose melatonin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose melatonin (1 mg for <40 kg; 2 mg for ≥40 kg)
Study: 32965037
Drug: High-dose melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose melatonin
Study: 32965037
Drug: Low-dose melatonin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose melatonin
Study: 39222391
Drug: Oral preparation
Normalized name: Iron bivalent, oral preparations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral preparation
Study: 34836393
Drug: 52 mL/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 52 mL/day of EVOO (n = 50)
Study: 34836393
Drug: DieTBra +
Approvals — FDA: no, EMA: no, PMDA: no
Description: DieTBra + 52 mL/day of EVOO (n = 50)
Study: 34822251
Drug: Topical anaesthetic
Normalized name: Topical anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anaesthetic (group A)
Study: 34822251
Drug: No anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anaesthetic gel (group B)
Study: 33080415
Drug: Norepinephrine 4
Normalized name: norepinephrine 4 MG per 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine 4 μg/min
Study: 35281034
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (15 µg daily for 12 weeks)
Study: 35281034
Drug: Vitamin D2
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin D2 (15 µg daily for 12 weeks)
Study: 35281034
Drug: Placebo (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (not specified dosage or duration)
Study: 33290248
Drug: Routine diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine diabetes care after discontinuation of rosiglitazone
Study: 32631074
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (simulated microcurrent electrical nerve stimulation) 5 days/week
Study: 32660521
Drug: Medium-volume preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-volume preparation
Study: 34779576
Drug: Upadacitinib (UPA)
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Upadacitinib (UPA) 15 mg
Study: 33472997
Drug: Closed-loop target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop target controlled infusion (CLTCI) of propofol
Study: 33472997
Drug: Open-loop target
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-loop target controlled infusion (OLTCI) of propofol
Study: 33628012
Drug: Bilayer tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilayer tablet of gemigliptin/rosuvastatin 50/20 mg
Study: 33628012
Drug: Monolayer tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monolayer tablet of gemigliptin/rosuvastatin 50/20 mg
Study: 33577389
Drug: Over-minus therapy
Normalized name: Arctium minus root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Over-minus therapy
Study: 33577389
Drug: Over-minus therapy
Normalized name: Arctium minus root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Over-minus therapy with inward decentration of spectacle glasses
Study: 34444341
Drug: Physical literacy-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical literacy-based intervention once weekly for 14 weeks
Study: 33503173
Drug: Controlled-release morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release morphine tablets combined with celecoxib
Study: 33503173
Drug: Controlled-release morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release morphine tablets alone (Control)
Study: 32100681
Drug: Nutrition intervention
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition intervention including lipid‐based nutrient supplements
Study: 33777422
Drug: Personalised physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalised physical activity consultations, pedometers, monthly messages via web-based application
Study: 34563169
Drug: Cabozantinib (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib (60 mg daily, orally)
Study: 33374947
Drug: 3 mg/kg/bm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg/bm of caffeine (3COF)
Study: 33374947
Drug: 6 mg/kg/bm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg/bm of caffeine (6COF)
Study: 38077080
Drug: Enhanced treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced treatment as usual (eTAU)
Study: 33895220
Drug: Optimal PEEP
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal PEEP (8.8 ± 2.4 cmH2O) with decremental titration after ARM
Study: 33601948
Drug: Local infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration analgesia (LIA) with 120 ml ropivacaine 0.2% plus epinephrine 0.5 µ/ml
Study: 33383447
Drug: SSS07 (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSS07 (5, 15, 30, 50, 75, and 100 mg)
Study: 33383447
Drug: SSS07 (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSS07 (lower doses)
Study: 33383447
Drug: SSS07 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSS07 (100 mg)
Study: 34049916
Drug: Daily Mile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Mile schools (intervention group)
Study: 34049916
Drug: Non-Daily Mile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-Daily Mile schools (control group)
Study: 32068436
Drug: NN‐Asp (originator
Approvals — FDA: no, EMA: no, PMDA: no
Description: NN‐Asp (originator insulin aspart)
Study: 35778368
Drug: Low-intensity shockwave
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity shockwave therapy (LiSWT)
Study: 35665521
Drug: Baclofen 10
Normalized name: baclofen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen 10 mg t.i.d.
Study: 32061505
Drug: Empiric broad-spectrum
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric broad-spectrum antibiotic therapy
Study: 32061505
Drug: Initial oral
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial oral or parenteral therapy
Study: 32061505
Drug: Shorter courses
Normalized name: SALICYLIC ACID 2 mg in 100 mL TOPICAL SHAMPOO [FYENACEL CALMING SHOOTER CELLANDIR HAIR LOSS-Shampoo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shorter courses of therapy
Study: 32061505
Drug: Antibiotic time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic time out protocol
Study: 34986194
Drug: Dietary intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary intervention of minimal and unprocessed foods for three to six months, including five times per week green vegetables, three times per week beef, daily 200-300 mL whole cow's milk (3.4% fat), and whole dairy butter (80% fat) on each slice of bread.
Study: 33323442
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (3 g/day of n-3 polyunsaturated fatty acids)
Study: 34560806
Drug: Reduced-dose alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-dose alteplase regimen
Study: 34560806
Drug: Standard heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard heparin anticoagulation
Study: 33538113
Drug: Tanezumab 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanezumab 2.5 mg subcutaneously every 8 weeks
Study: 33538113
Drug: Tanezumab 5
Normalized name: tanezumab
DrugBank: Tanezumab (DB12335)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanezumab 5 mg subcutaneously every 8 weeks
Study: 33538113
Drug: NSAIDs (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDs (oral naproxen, celecoxib, or diclofenac twice daily)
Study: 33993064
Drug: Testosterone therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone therapy (TTh) for 2 years
Study: 32844712
Drug: Placebo during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo during the first year, followed by Testosterone therapy (TTh) during the second year
Study: 35418412
Drug: Test-and-treat plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test-and-treat plus L. reuteri
Study: 35418412
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care plus L. reuteri
Study: 33554885
Drug: Low power
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low power laser therapy (LPLT) for 15 sessions
Study: 34542830
Drug: Galcanezumab (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galcanezumab (120 mg/month with 240 mg loading dose)
Study: 34542830
Drug: Galcanezumab (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galcanezumab (120 mg/month)
Study: 33109271
Drug: Group Post‐Admission
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Post‐Admission Cognitive Therapy for Suicidality (GPACTS)
Study: 38176391
Drug: Individual Supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual Supportive Therapy (IST)
Study: 32348539
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injection every 4 weeks (2q4)
Study: 32348539
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injection every 8 weeks (2q8)
Study: 36047018
Drug: Limited protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limited protocol (LP) - limited-frequency ultrasound monitoring (only at end of treatment)
Study: 35046508
Drug: Intravenous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous placebo (n=54)
Study: 35046508
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose ketamine (0.2 mg/kg; n=53)
Study: 35046508
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose ketamine (0.5 mg/kg; n=51)
Study: 33909353
Drug: Acupuncture as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture as adjunctive therapy
Study: 34655432
Drug: Cetagliptin 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetagliptin 400 mg
Study: 34655432
Drug: Cetagliptin (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetagliptin (various doses 12.5-400 mg)
Study: 35579606
Drug: Moderate walking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate walking exercise (150 minutes weekly, 3 times a week for 12 weeks)
Study: 35579606
Drug: Vigorous walking
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vigorous walking exercise (75 minutes weekly, 3 times a week for 12 weeks)
Study: 36129240
Drug: TAT patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAT patch
Study: 34447995
Drug: Early rhythm
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early rhythm control therapy in asymptomatic patients (395/801)
Study: 34447995
Drug: Early rhythm
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early rhythm control therapy in symptomatic patients
Study: 34215703
Drug: belimumab 10
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: belimumab 10 mg/kg every 28 days for ?7 years
Study: 35304924
Drug: adamgammadex 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: adamgammadex 2 mg.kg-1
Study: 35304924
Drug: adamgammadex 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: adamgammadex 4 mg.kg-1
Study: 35304924
Drug: adamgammadex 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: adamgammadex 6 mg.kg-1
Study: 35304924
Drug: adamgammadex 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: adamgammadex 8 mg.kg-1
Study: 33359562
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (NDT group)
Study: 35134489
Drug: Henna mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Henna mouthwash (2% aqueous extract, prescribed twice daily)
Study: 35134489
Drug: Chlorhexidine gluconate
Normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine gluconate 0.2% mouthwash (prescribed twice daily)
Study: 35026987
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (various pre/post-partum dose combinations)
Study: 34079227
Drug: Dezocine 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dezocine 0.8 mg/kg (Group D)
Study: 34079227
Drug: Sufentanil 2
Normalized name: SUFentanil 250 MCG in 5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 2 µg/kg (Group S)
Study: 32909365
Drug: 180 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mg of Ellagic acid per day
Study: 32641142
Drug: Extracorporeal shockwave
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shockwave therapy (ESWT) in addition to conventional therapy
Study: 32641142
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment including medication therapy and invasive interventional therapy
Study: 32307431
Drug: Mexidol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexidol (500 mg IV once daily for 14 days, then Mexidol Forte 250 (250 mg, 3 times a day for 60 days)
Study: 32307431
Drug: Standard basic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard basic therapy (comparison group)
Study: 32056985
Drug: High-intensity negative
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity negative ion patch treatment
Study: 32483770
Drug: Desmopressin (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin (0.3 μg/kg)
Study: 32450915
Drug: SOC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC plus hydroxychloroquine monotherapy
Study: 34229074
Drug: Placebo intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intravenous infusion